Charles A. Deignan is CFO at Clearside Biomedical, Inc. (CLSD). They have made 6 open-market trades across 1 company since 2016, most recently 2024-01-19.
CIK 0001664690
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
4 open-market purchases totalling $35K since 2017, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CLSD | 384,662 | $158K |
Shares reported on the most recent Form 4, priced at the 2024-01-19 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CLSD | SELL | 2024-01-19 | 2024-01-19 | $1.28 | $17K | +0.0% | +3.2% | +5.6% |
| CLSD | SELL · 10b5-1 | 2023-01-19 | 2023-01-20 | $1.50 | $21K | +1.3% | -9.9% | -26.3% |
| CLSD | SELL · 10b5-1 | 2022-01-19 | 2022-01-20 | $2.09 | $18K | +0.0% | -22.6% | -2.1% |
| CLSD | SELL · 10b5-1 | 2021-09-21 | 2021-09-23 | $6.41 | $18K | -25.1% | -17.6% | -56.8% |
| CLSD | SELL · 10b5-1 | 2021-06-21 | 2021-06-23 | $4.37 | $13K | +6.5% | -1.3% | +25.2% |
| CLSD | SELL · 10b5-1 | 2020-06-01 | 2020-06-03 | $1.88 | $28K | +7.3% | +0.0% | -12.0% |
| CLSD | BUY | 2019-11-12 | 2019-11-13 | $1.14 | $9K | +13.5% | +63.1% | +152.3% |
| CLSD | BUY | 2019-03-15 | 2019-03-18 | $1.36 | $14K | -2.1% | -10.0% | -26.4% |
| CLSD | BUY | 2018-03-23 | 2018-03-26 | $11.79 | $6K | -12.4% | -4.1% | -15.1% |
| CLSD | BUY | 2017-08-14 | 2017-08-14 | $7.07 | $7K | -3.2% | +4.4% | +2.4% |
| CLSD | SELL | 2016-06-07 | 2016-06-07 | $7.00 | $14 | +1.4% | -3.0% | +15.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.